Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations

Retinal vein occlusion (RVO) represents a heterogeneous group of disorders that remains the second most common retinal vascular disease and can be associated with vision loss. RVO confers a substantial burden of illness that affects patients, caregivers, medical systems, and physicians. Complications of RVO – including cystoid macular edema, macular ischemia, and neovascularization sequelae – may result in severe visual morbidity and blindness. Canadian expert consensus recommendations on the optimal treatment of patients with RVO were published in 2015. Since that time, advances in diagnosis and pharmacotherapy have been made, changing the clinical approach of retina specialists. This article presents updated data and recommendations for the management of patients with RVO.